<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20923711</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>49</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.</ArticleTitle><Pagination><StartPage>7731</StartPage><EndPage>7736</EndPage><MedlinePgn>7731-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2010.09.065</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a growing public health concern, especially in Asia. A surge of EV71 cases in 2008 prompted authorities in China to go on national alert. While there is currently no treatment for EV71 infections, vaccines are under development. We developed a computer simulation model to determine the potential economic value of an EV71 vaccine for children (&lt;5 years old) in China. Our results suggest that routine vaccination in China (EV71 infection incidence &#x2248;0.04%) may be cost-effective when vaccine cost is $25 and efficacy &#x2265;70% or cost is $10 and efficacy &#x2265;50%. For populations with higher infection risk (&#x2265;0.4%), a $50 or $75 vaccine would be highly cost-effective even when vaccine efficacy is as low as 50%.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Bruce Y</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Public Health Computational and Operations Research (PHICOR), School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, United States. BYL1@pitt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wateska</LastName><ForeName>Angela R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Rachel R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Julie H Y</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Bacon</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM088491</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM088491-01</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U54GM088491-0109</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="Y">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20923711</ArticleId><ArticleId IdType="mid">NIHMS247228</ArticleId><ArticleId IdType="pmc">PMC2989421</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2010.09.065</ArticleId><ArticleId IdType="pii">S0264-410X(10)01386-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsiung GD, Wang JR. Enterovirus infections with special reference to enterovirus 71. J Microbiol Immunol Infect. 2000;33(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer MH. Enterovirus infections: diagnosis and treatment. Curr Opin Pediatr. 2001;13(1):65&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176247</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol. 2005;11(5):424&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect. 2000;33(4):205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SS, et al. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect. 2010:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, et al. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84(1):661&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;26(23):2882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, et al. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol. 2008;82(4):1787&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine. 2010;28(16):2806&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385993</ArticleId><ArticleId IdType="pubmed">19782109</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRoeck D, et al. Policymakers' views regarding the introduction of new- generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine. 2005;23(21):2762&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15780724</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109(6):e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF. Info by country: China Statistics. 2007. Jan 24,  2010]; Available from:  http://www.unicef.org/infobycountry/china_statistics.html.</Citation></Reference><Reference><Citation>Walker D, Beutels P. WHO guide for standardization of economic evaluations of immunization programmes. Department of Immunization Vaccines and Biologicals; Geneva: 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">19567247</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP) 2007.</Citation></Reference><Reference><Citation>Pichichero ME, et al. Clinical and economic impact of enterovirus illness in private pediatric practice. Pediatrics. 1998;102(5):1126&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794944</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Estimates of Unit Costs for Patient Services for China. Choosing Interventions that are Cost Effective.  [cited 2/19/2010]; Available from:  http://www.who.int/choice/country/chn/cost/en/index.html.</Citation></Reference><Reference><Citation>World Health Organization. Estimates of Unit Costs for Patient Services for United States of America. Choosing Interventions that are Cost Effective.  [cited 2/19/2010]; Available from:  http://www.who.int/choice/country/usa/cost/en/index.html.</Citation></Reference><Reference><Citation>Adam T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc. 2003;1(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156022</ArticleId><ArticleId IdType="pubmed">12773218</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldie SJ, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007;25(33):6257&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17606315</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D, et al. The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS One. 2007;2(1):e750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1939734</ArticleId><ArticleId IdType="pubmed">17710149</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Vaccine Management and Logistics: Vaccine Volume Calculator. 2009. Sept 13,  2010]; Available from:  http://www.who.int/immunization_delivery/systems_policy/logistics/en/index4.html.</Citation></Reference><Reference><Citation>Lee BY, McGlone SM. Pricing of New Vaccines. Human Vaccines. 2010;6(8):619&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056061</ArticleId><ArticleId IdType="pubmed">20861678</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis. 2005;192(Suppl 1):S133&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeuland M, et al. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009;12(6):899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">19824189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51(2):405&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245734</ArticleId><ArticleId IdType="pubmed">19839061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention and the Office of the World Health Organization in China. Report on the hand, foot and mouth disease outbreak in Fuyang City, Anhui Province and the prevention and control in China, May 2008.  2/15/2010]; Available from:  http://www.wpro.who.int/NR/rdonlysres/591D6A7B-FB15-4E94-A1E9-1D3381847D60/0/HFMDCCDC20080515ENG.pdf.</Citation></Reference><Reference><Citation>van der Sanden S, et al. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol. 2009;47(9):2826&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738086</ArticleId><ArticleId IdType="pubmed">19625480</ArticleId></ArticleIdList></Reference><Reference><Citation>Podin Y, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health. 2006;6:180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1543637</ArticleId><ArticleId IdType="pubmed">16827926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert GL, et al. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7(7):484&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, et al. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet. 1974;2(7872):112.</Citation><ArticleIdList><ArticleId IdType="pubmed">4136956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindarov LM, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol. 1979;23(3):284&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">231067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G, et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71(3):217&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28(20):3516&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>